Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.820
-0.090 (-4.71%)
Apr 29, 2026, 9:34 AM EDT - Market open
Esperion Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 167.85 | 144.76 | 82.25 | 124.78 | 208.89 | Upgrade
|
| Short-Term Investments | - | - | - | 42.09 | 50.44 | Upgrade
|
| Cash & Short-Term Investments | 167.85 | 144.76 | 82.25 | 166.86 | 259.33 | Upgrade
|
| Cash Growth | 15.95% | 76.00% | -50.71% | -35.66% | -14.96% | Upgrade
|
| Receivables | 140.19 | 80.14 | 48.49 | 33.73 | 22.93 | Upgrade
|
| Inventory | 145.99 | 108.35 | 65.62 | 35.2 | 34.39 | Upgrade
|
| Prepaid Expenses | 8.54 | 4.74 | 4.7 | 10.89 | 12.31 | Upgrade
|
| Total Current Assets | 462.57 | 338 | 201.07 | 246.68 | 328.97 | Upgrade
|
| Property, Plant & Equipment | 3.26 | 5.77 | 4.68 | 1.2 | 2.56 | Upgrade
|
| Other Intangible Assets | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | Upgrade
|
| Other Long-Term Assets | - | - | - | - | 50 | Upgrade
|
| Total Assets | 465.89 | 343.82 | 205.8 | 247.94 | 381.59 | Upgrade
|
| Accounts Payable | 65.07 | 51.65 | 31.72 | 23.04 | 17.56 | Upgrade
|
| Accrued Expenses | 23.36 | 24.63 | 28.44 | 18.63 | 21.23 | Upgrade
|
| Current Portion of Long-Term Debt | 87.6 | 102.16 | 34.83 | 24.76 | 11.3 | Upgrade
|
| Current Portion of Leases | 2.1 | 2.74 | 1.55 | 0.38 | 1.39 | Upgrade
|
| Current Unearned Revenue | 34.48 | 8.52 | 25.4 | 3.51 | 5.68 | Upgrade
|
| Other Current Liabilities | 88.2 | 56.54 | 34.28 | 21.99 | 16.19 | Upgrade
|
| Total Current Liabilities | 300.81 | 246.23 | 156.22 | 92.31 | 73.35 | Upgrade
|
| Long-Term Debt | 457.65 | 483.74 | 501.55 | 478.74 | 504.02 | Upgrade
|
| Long-Term Leases | 0.65 | 2.57 | 3.02 | 0.67 | 0.52 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | - | 0.63 | Upgrade
|
| Other Long-Term Liabilities | 8.74 | - | - | - | - | Upgrade
|
| Total Liabilities | 767.85 | 732.54 | 660.79 | 571.72 | 578.53 | Upgrade
|
| Common Stock | 0.25 | 0.2 | 0.12 | 0.08 | 0.06 | Upgrade
|
| Additional Paid-In Capital | 1,376 | 1,267 | 1,149 | 1,071 | 964.4 | Upgrade
|
| Retained Earnings | -1,624 | -1,601 | -1,549 | -1,340 | -1,106 | Upgrade
|
| Treasury Stock | -55 | -55 | -55 | -55 | -55 | Upgrade
|
| Comprehensive Income & Other | - | - | - | -0 | -0.03 | Upgrade
|
| Shareholders' Equity | -301.97 | -388.72 | -454.99 | -323.78 | -196.94 | Upgrade
|
| Total Liabilities & Equity | 465.89 | 343.82 | 205.8 | 247.94 | 381.59 | Upgrade
|
| Total Debt | 548 | 591.21 | 540.95 | 504.55 | 517.24 | Upgrade
|
| Net Cash (Debt) | -380.15 | -446.45 | -458.7 | -337.69 | -257.9 | Upgrade
|
| Net Cash Per Share | -1.83 | -2.39 | -4.45 | -5.09 | -8.92 | Upgrade
|
| Filing Date Shares Outstanding | 256.81 | 197.85 | 185.05 | 76.57 | 62.82 | Upgrade
|
| Total Common Shares Outstanding | 245.22 | 195.85 | 118.21 | 74.57 | 60.88 | Upgrade
|
| Working Capital | 161.76 | 91.77 | 44.84 | 154.38 | 255.62 | Upgrade
|
| Book Value Per Share | -1.23 | -1.98 | -3.85 | -4.34 | -3.23 | Upgrade
|
| Tangible Book Value | -302.02 | -388.78 | -455.05 | -323.83 | -197 | Upgrade
|
| Tangible Book Value Per Share | -1.23 | -1.99 | -3.85 | -4.34 | -3.24 | Upgrade
|
| Machinery | 0.86 | 0.86 | 0.86 | 1.45 | 1.45 | Upgrade
|
| Construction In Progress | 0.19 | - | - | - | - | Upgrade
|
| Leasehold Improvements | 0.19 | 0.19 | 0.19 | 0.3 | 0.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.